[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"elevated-lpa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:elevated-lpa":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100605073","phase-3-assessing-the-impact-of-muvalaplin-on-major-cardiovascular-events-in-adults-with-elevated-lipoproteina-100605073",false,"NCT07157774","Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event","MOVE-Lp(a)","Inclusion Criteria:\n\n* Have Lp(a) ≥175 nanomoles per liter (nmol\u002FL)\n* Meet one of the following criteria:\n\n  * Have had a prior atherosclerotic cardiovascular disease (ASCVD) event (such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body) within 10 years prior to screening\n  * Are at risk for a first ASCVD event, defined as one or more of the following:\n\n    * Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without a history of ASCVD event\n    * A high coronary artery calcium (CAC) score\n    * Reduced kidney function with diabetes\n    * Combination(s) of high risk factors\n\nExclusion Criteria:\n\n* Have experienced a major cardiovascular event or surgery, such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body, within 90 days prior to screening or occurring between screening and randomization\n* Are planning or expected to undergo a procedure to restore blood flow in the arteries or a major heart surgery during the study\n* Have uncontrolled high blood pressure\n* Have New York Heart Association (NYHA) class III or IV heart failure\n* Have undergone a procedure to remove cholesterol from the blood within 90 days of screening, or have a planned procedure during the study\n* Have severe kidney impairment\n* Have had cancer within 5 years prior to screening","ALL","18 Years",{"count":20,"type":21},10450,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.",[27,28],"Elevated Lp(a)","Atherosclerotic Cardiovascular Disease (ASCVD)","RECRUITING","2026-06-19",{"date":32,"type":33},"2026-06-23","ACTUAL",{"date":35,"type":33},"2025-09-02",{"date":37,"type":21},"2031-03",{"name":39,"class":40},"Eli Lilly and Company","INDUSTRY",762,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100608165","2-hoba-supplementation-in-people-with-elevated-lipoproteina-100608165","NCT07198009","2-HOBA Supplementation in People With Elevated Lipoprotein(a)","Modulation of Bioactive Lipids in Lipid Disorders: a Pilot Study of 2-HOBA Supplementation in Individuals With Elevated Lipoprotein(a)","Inclusion Criteria:\n\n* Males and females aged 18-69 years.\n* Elevated Lp(a) levels ≥ 90 mg\u002FdL.\n* Able to provide informed consent and adhere to study schedules.\n* Willing to follow a physician-recommended diet during the study.\n\nExclusion Criteria:\n\n* Pregnant, planning pregnancy during the study period, or currently breastfeeding.\n* Individuals with established cardiovascular disease\n* Planning major changes in diet or exercise routines.\n* Experienced \\>20% weight change in the past 3 months.\n* Diagnosed with malabsorption syndrome or chronic diarrhea.\n* Abnormal liver, kidney, or thyroid function.\n* Drug or alcohol abuse within the past 6 months, or significant mental\u002Fpsychological impairment.\n* Have known bleeding disorders (e.g., hemophilia).\n* Planned surgery during the study period.\n* Donated blood within the last 2 weeks or planning to donate during the study.\n* Require regular blood transfusions.","69 Years",{"count":51,"type":21},10,[53],"NA","The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels.\n\nThe main questions it aims to answer are:\n\nDoes 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood?\n\nParticipants will:\n\nTake 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers",[56,27],"Hyperlipidemia",[58,59,60],"Oxidized Phospholipids","lp(a)","2HOBA","NOT_YET_RECRUITING","2025-09-25",{"date":64,"type":33},"2025-09-30",{"date":66,"type":21},"2025-11-01",{"date":68,"type":21},"2026-11",{"name":70,"class":71},"The Miriam Hospital","OTHER",1]